Désiré Collen
Désiré Collen (born 21 June 1943) is a Belgian physician and chemist. He was born in Sint-Truiden, Belgium.
Education
He graduated as an M.D. at the Katholieke Universiteit Leuven in 1968 and obtained a PhD in chemistry in 1974.
Career
He started his career as in 1968-1971 as a Resident in Internal Medicine at the University Hospitals of the Katholieke Universiteit Leuven. Since 2002 he has been a professor at the Centre for Molecular en Vascular Biology, and he is also head of the VIB Département of Transgene Technology and Gene Therapy, K.U.Leuven. Together with professor Billiau he discovered Tissue plasminogen activator (tPA) in 1979.[1][2][3] He is the founder of the Flemish biotech company Thromb-X.
Awards
- 1984: Francqui Prize on Biological and Medical Sciences.
- 1985: Louis-Jeantet Prize for Medicine, together with Luc Montagnier and Michael Berridge.
- 2005: Interbrew-Baillet Latour Health Prize, together with Peter Carmeliet.[4]
References
- ^ Collen D, Billiau A, Edy J, De Somer P., Identification of the human plasma protein which inhibits fibrinolysis associated with malignant cells, Biochim Biophys Acta. 1977 September 29;499(2):194-201
- ^ Collen D, Verstraete M. Systemic thrombolytic therapy of acute myocardial infarction? Circulation. 1983 Aug;68(2):462–465
- ^ Collen D. Human tissue-type plasminogen activator: from the laboratory to the bedside. Circulation. 1985 Jul;72(1):18–20
- ^ Bloom S., Belgian scientists awarded top honors, J Clin Invest. 2005 May;115(5):1106-7
External links
| International | |
|---|---|
| National | |
| Other | |
.svg){kind=small}   | This article about a Belgian scientist is a stub. You can help Wikipedia by expanding it. |